Much of the focus of the preeclampsia research field span across these four categories: “prediction”, “prevention”, “treatments”, and “outcomes” from preeclampsia (short- and long-term morbidity and mortality). The highest risk/reward research, but arguably the most difficult, is in the prevention and treatment categories. Right now, low-dose aspirin is the most common medication consistently recommended to lower risk for preeclampsia. There is a lack of any other medications/therapeutics on the market approved to prevent or cure preeclampsia once it develops. (It is important to note that magnesium sulfate is highly effective and approved for preventing and treating eclamptic seizures. It does not, however, halt the progression of the high blood pressure which characterizes preeclamspia.)
Research is being done to make a medicine that can cure preeclampsia a reality. In this article, researchers asked: what are the candidate medicines being studied currently to prevent or treatment preeclampsia? After an extensive review of the literature and clinical trial databases, researchers of this article identified 87 candidate medicines in clinical development. Within that list, researchers classified 7 as “high potential” and 8 as “medium potential”. Some of the candidate medicines for preventing preeclampsia listed include: esomeprazole, L-arginine, vitamin D, metformin, probiotic lactobacilli, selenium. Some of the candidate medicines listed for treatment of preeclampsia included: sulfasalazine, metformin, pravastatin, and omega-3 fatty acid.
Take home message: Research that puts together all of the current research in one place is helpful to set the direction for new studies and research funding. Gathering information on all the potential preeclampsia treatments or preventions in one article, to report and evaluate what has been done so far, helps move the research & development field for preeclampsia medicines forward.
Link: https://rdcu.be/cYYyS
Citation: McDougall ARA, Hastie R, Goldstein M, Tuttle A, Tong S, Ammerdorffer A, Gülmezoglu AM, Vogel JP. Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles. BMC Med. 2022 Nov 4;20(1):393. doi: 10.1186/s12916-022-02582-z. PMID: 36329468; PMCID: PMC9635102.
Each quarter, our team of researchers reviews the most current studies related to hypertensive disorders of pregnancy and selects those studies they feel will be of greatest interest to our community to summarize.
Special thanks to our volunteer research team, who under the leadership of Dr. Elizabeth Sutton, make Research Roundup possible: Alisse Hauspurg, MD Felicia LeMoine, and MD Jenny Sones, PhD, DVM.
Development and validation of a new algorithm for improved cardiovascular risk prediction Heart disease or cardiovascular disease (CVD) is a leading cause of death worldwide. An individual&r...
Women With a History of Preeclampsia Exhibit Accelerated Aging and Unfavorable Profiles of Senescence Markers Scientists conducted a study to see if women with preeclampsia were more likely...
Feasibility of home-based treatment among participants in a remote postpartum hypertension program Postpartum hypertension (high blood pressure after pregnancy) is the most common reason for...
Postpartum Ambulatory Blood Pressure Patterns Following New-Onset Hypertensive Disorders of Pregnancy After experiencing gestational hypertension or preeclampsia, high blood pressure can wors...
Patterns of Gestational Hypertension or Preeclampsia Across 2 Pregnancies in Relationship to Chronic Hypertension Development: A Retrospective Cohort Study Experiencing preeclampsia or gestat...